Metsera Inc. Receives “Hold” Rating from Analysts Amid Market Activity

Metsera Inc. (NASDAQ:MTSR) has received a consensus rating of “Hold” from eight analysts currently covering the biopharmaceutical company. According to a report by MarketBeat Ratings, one analyst has assigned a sell rating, while three analysts have given the stock a hold rating and four have rated it as a buy. The average twelve-month target price set by brokerage firms monitoring Metsera is $55.75.

Several analysts have recently shared their insights on Metsera’s stock performance. On September 3, 2023, analysts from Cantor Fitzgerald reiterated an “overweight” rating for Metsera, emphasizing confidence in the company’s potential. Conversely, on October 1, 2023, Wall Street Zen upgraded Metsera’s rating from sell to hold, indicating a more favorable outlook.

Bank of America raised its target price on Metsera shares from $45.00 to $50.00, maintaining a buy rating in a report published on August 28, 2023. In contrast, Wells Fargo & Company downgraded Metsera from an “overweight” rating to an “equal weight” rating, setting a price target of $54.00 in a report dated September 30, 2023. Additionally, Leerink Partners reduced its rating from “strong buy” to “hold” on September 24, 2023.

Investor Activity and Market Performance

Recent trading activity shows that several large investors have adjusted their positions in Metsera. Legal & General Group Plc increased its stake by 1.1% during the third quarter, now owning 23,491 shares valued at approximately $1.23 million after acquiring an additional 245 shares. Osaic Holdings Inc. boosted its position by 45.5% during the second quarter, bringing its total holdings to 946 shares worth around $27,000.

The Swiss National Bank also expanded its holdings by 1.5% in the third quarter, now possessing 40,700 shares valued at about $2.13 million following the purchase of 600 shares. Notably, BNP Paribas Financial Markets doubled its stake by acquiring 1,600 shares during the second quarter, worth $46,000 after buying an additional 800 shares. Caitong International Asset Management Co. Ltd. entered the market with a new stake valued at approximately $44,000 in the third quarter.

Metsera’s stock performance reflects significant fluctuations. On November 12, 2023, the company announced its quarterly earnings, reporting earnings per share (EPS) of ($1.11), which fell short of the consensus estimate of ($0.56) by $0.55. As of the latest trading session, Metsera shares opened at $70.50. The stock has experienced a 50-day moving average of $62.33 and a 200-day moving average of $43.97. With a market capitalization of approximately $7.42 billion and a price-to-earnings (PE) ratio of -11.16, Metsera has seen a one-year low of $12.30 and a high of $83.86.

About Metsera Inc.

Metsera Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides aimed at treating obesity, overweight, and related conditions. The company’s product pipeline includes several candidates, such as MET-097i, MET-233, and MET-224o.

As the market continues to evolve, investors are closely monitoring Metsera’s performance and the implications of recent analyst ratings and investor movements.